Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway

Xingcong Ma1
Wanjun Yan1
Zhijun Dai1
Xiaoyan Gao1
Yinan Ma1
Quntao Xu1
Jiantao Jiang1
Shuqun Zhang1

1Department of Oncology, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China; 2Department of Oncology, Institute of Health, China North Industries Group Corporation, Xi’an, Shaanxi, People’s Republic of China; 3Department of Thoracic Surgery, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China

Background: The flavonoid baicalein, a historically used Chinese herbal medicine, shows a wide range of biological and pharmaceutical effects, among which its potent antitumor activity has raised great interest in recent years. However, the molecular mechanism involved in the antimetastatic effect of baicalein remains poorly understood. This study aimed to verify the inhibitory effects of baicalein on metastasis of MDA-MB-231 human breast cancer cells both in vitro and in vivo, as well as to investigate the related mechanisms.

Methods: MTT assay was used to examine the inhibition of baicalein on proliferation of MDA-MB-231 cells. Wound healing assay and the in vitro invasion assay was carried out to investigate the effects of baicalein on migration and invasion of MDA-MB-231 cells, respectively. In order to explore the effects of baicalein on tumor metastasis in vivo, xenograft nude mouse model of MDA-MB-231 cells was established. Animals were randomly divided into four groups (control, therapy group, and low-dose and high-dose prevention group, n=6), and treated with baicalein as designed. Following sacrifice, their lungs and livers were collected to examine the presence of metastases. qRT-PCR and Western blot were performed to study the effects of baicalein on expression of SATB1, EMT-related molecules, and Wnt/β-catenin signaling components of MDA-MB-231 cells as well as the metastatic tissue. Effects of baicalein on the expression of target proteins in vivo were also analyzed by immunohistochemistry.

Results: Our results indicated that baicalein suppressed proliferation, migration, and invasion of MDA-MB-231 cells in a time- and dose-dependent manner. Based on assays carried out in xenograft nude mouse model, we found that baicalein inhibited tumor metastasis in vivo. Furthermore, baicalein significantly decreased the expression of SATB1 in MDA-MB-231 cells. It suppressed the expression of vimentin and SNAIL while enhancing the expression of E-cadherin. Baicalein also downregulated the expression of Wnt1 and β-catenin proteins and transcription level of Wnt/β-catenin-targeted genes.

Conclusion: Our results demonstrate that baicalein has the potential to suppress breast cancer metastasis, possibly by inhibition of EMT, which may be attributed to downregulation of both SATB1 and the Wnt/β-catenin pathway. Taken together, baicalein may serve as a promising drug for metastasis treatment of breast cancer.

Keywords: breast cancer, baicalein, metastasis, EMT, SATB1, Wnt/β-catenin pathway

Background
Breast cancer is the most common malignancy and the leading cause of cancer-related death among women worldwide. Although reliable statistics suggests a downtrend of mortality in the past 20 years, the incidence of breast cancer is continuously climbing, especially in many developing countries where breast cancer incidence used to be...
very low. Women aged between 20 and 59 years are most likely to be inflicted by breast cancer, and the age of onset has reduced in recent years, posing a big threat to women’s health and life quality. Despite the improvement of surgical treatment, radiotherapy and chemotherapy, metastasis remains incurable and is the main cause of breast cancer-related death. Research in this field must concentrate on the investigation of metastatic mechanisms, reliable molecular markers, and therapeutic targets for breast cancer, thus promoting the exploration of effective drugs.

Metastasis is defined as the process by which malignant tumor cells break away from their primary site, invade the surrounding tissue, intravasate into microvasculature, then translocate to distant organs through lymphatic or blood vessels, exit from the circulatory system, survive in new microenvironment, and finally develop a homogeneous tumor at the secondary site. Invasiveness and metastatic potential are two important biological characteristics of cancers. These malignant behaviors are comprised of multiple steps and involve systemic damages, laying the pathologic basis of tumor relapse and disease deterioration. It is estimated that metastasis accounts for 90% of cancer-related mortality.

The special AT-rich sequence-binding protein-1 (SATB1) is a specifically expressed matrix attachment regions (MARs)-binding protein. It is mainly expressed in the thymocytes, remains at low level in the testes, the fetal brain, and the osteoblasts, and is hardly detectable in other normal tissues. SATB1 specifically binds MARs with high affinity and provides an anchorage platform for hundreds of genes, thus regulating their expression and changing cell phenotype through excessive genetic recombination. The genes regulated by SATB1 count for 2%–10% of the genome. SATB1 was first identified in the T-cells. It regulates the spatial and temporal expression of genes during the differentiation and maturation of T-cells and guarantees their normal development. Recent studies have shown that SATB1 regulates the malignant progression of breast cancer. It is expressed during oncogenesis and changes the expression pattern of genes. Tumor cells then acquire aggressive phenotype and the ability to metastasize. Activation of SATB1 is indispensable for tumor metastasis, for it enhances the expression of various genes involved in the growth, proliferation, angiogenesis, invasion, and metastasis. High level of SATB1 predicts bad outcome for breast cancer patients. Further researches indicate that SATB1 is overexpressed in gastric, colorectal, liver, ovarian, prostate, and bladder cancers. These findings suggest an important role of SATB1 in the initiation and development of cancers.
In this study, we verified that baicalein significantly suppressed the proliferation, migration, and invasion of breast cancer cell line MDA-MB-231 in vitro. Results of assays carried out in xenograft nude mouse model also indicated an inhibitive effect of baicalein on tumor metastasis in vivo. Chung et al reported that baicalein suppresses the EMT of breast epithelial cells; the tumorigenic activity of breast cancer cells, which indicated that inhibition of EMT, may play an important part in antitumor effect of baicalein. Additionally, we reported a novel mechanism for the antimetastatic effect of baicalein—suppression of EMT—which may be attributed to the cooperative inhibition of SATB1 and Wnt/β-catenin pathway. Furthermore, appealing is that our findings suggest potential cross talk between SATB1 and Wnt/β-catenin signaling during the progression of breast cancer, providing a new perspective to study the regulation mechanisms of cancers.

Materials and methods

Cell culture and reagents

Immortalized mammary epithelial cells (MCF-10A) were obtained from Sagene Biological Technology Co., Ltd. (Guangzhou, People’s Republic of China). MCF7, SKBR3, and MDA-MB-231 human breast cancer cell lines were obtained from Shanghai Cell Biological Institute of the Chinese Academy of Science (Shanghai, People’s Republic of China). MCF-10A cells were cultured in mammary epithelial growth medium supplemented with 100 ng/mL cholera toxin (Sagene Biological Technology Co., Ltd). MCF7, SKBR3, and MDA-MB-231 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS; Hyclone) and 1% penicillin–streptomycin solution (Thermo Fisher Scientific, Waltham, MA, USA) and maintained in a cell incubator with a humidified atmosphere of 95% air and 5% CO₂ at 37°C.

MTT [3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl]-2H-tetrazolium] and baicalein were purchased from Sigma-Aldrich (St Louis, MO, USA) and stored at −20°C in the dark. The stock solution of baicalein for incubation with cells was prepared in dimethyl sulfoxide (DMSO; MP Biomedicals, Santa Ana, CA, USA) and further diluted in culture medium. Final concentration of DMSO in the medium was 0.1% (to avoid its interference with cell viability). Carboxymethyl cellulose sodium (CMC-Na) was purchased from Sigma-Aldrich. 3,3’-Diaminobenzidine (DAB) was from Prototech (Beijing, People’s Republic of China). β-Catenin rabbit mAb (D10A8), E-cadherin rabbit mAb (D21H3), and vimentin rabbit mAb (D21H3) were purchased from Cell Signaling Technology (Danvers, MA, USA). SATB1 (ab92307), SNAIL (ab180714) monoclonal antibodies, and Wnt1 (ab85060) polyclonal antibody were purchased from Abcam (Cambridge, MA, USA). Anti-β-actin antibody was obtained from Santa Cruz Biotechnology Inc. (Dallas, TX). Horseradish peroxidase (HRP)-linked goat anti-mouse or anti-rabbit immunoglobulin G (IgG) antibodies were purchased from ComWin Biotech Co., Ltd. (Beijing, People’s Republic of China). Baicalein treatment and extraction of RNA and protein were all performed during the logarithmic growth phase of cells.

MTT assay

MTT assay was conducted to evaluate the effect of baicalein on proliferation of breast cancer cells. MDA-MB-231 cells were routinely digested, collected, and then seeded in 96-well plates at a density of 8×10³ cells/well. After incubation for 12–24 hours, cells were treated with 0, 20, 40, 60, 80, 100, and 120 μmol/L baicalein according to their experimental grouping and then incubated at 37°C for 24, 48, and 72 hours. At the end of baicalein treatment, 20 μL MTT solution at a concentration of 5 mg/mL was added into each well and the incubation continued for another 4 hours. Then the medium was removed and 160 μL/well DMSO was added. The optical density (OD) value of each well was measured spectrophotometrically at 490 nm. The inhibition ratio (IR) was calculated according to the following formula: IR = (1–mean OD value of experimental group/mean OD value of control group) × 100%. Approximately 50% inhibition concentration (IC₅₀) of baicalein at different time points was calculated using the Logit method.

Wound healing assay

Wound healing assay was used to evaluate the migration ability of breast cancer cells. MDA-MB-231 cells were seeded into the six-well plates at a density of 1×10⁶ cells/well and incubated in medium containing 10% FBS. When the cell monolayer reached 80% confluency, a 200 μL pipette tip was used to scratch a straight wound tract through the middle of the cell monolayer. Each well was gently washed with phosphate-buffered saline (PBS) three times to remove the detached cells. Then, the MDA-MB-231 cells were incubated in medium containing 2% FBS and 0, 10, 20, and 40 μmol/L baicalein for up to 24 hours. Pictures were taken under 40× magnification at 0, 12, and 24 hours after baicalein was added. The cell migration distance was presented as an average value assessed by using Photoshop software (Adobe, San Jose, CA, USA). Each experiment was performed three times. The relative migration distance was determined as a percentage of the control.
In vitro invasion assay
The in vitro invasive potential of breast cancer cells was assessed by use of the Transwell chamber with 10 mm diameter and 8 μm pore size polycarbonate membrane (Millipore, Billerica, MA, USA) coated with Matrigel (BD, Franklin Lakes, NJ, USA), according to manufacturer’s instructions. MDA-MB-231 cells were pretreated with baikalein (0, 10, 20, and 40 μmol/L) for 24 hours. Then cells were collected and resuspended to a final density of 5×10⁴ cells/mL and added into each upper chamber of Transwell system. After 24 hours of incubation at 37°C, cells that remained on the upper side of the polycarbonate membrane were removed with a cotton swab and the invaded cells were fixed and stained with crystal violet. Ten fields on each membrane were randomly selected and the number of invaded cells was counted. Pictures were taken under 100× magnification. The experiment was repeated three times.

Establishment of the xenograft nude mouse model of breast cancer metastasis
To explore the effects and mechanisms of baikalein on tumor metastasis in vivo, a xenograft nude mouse model of MDA-MB-231 cells was established. After 1 week acclimation, nude mice were injected (through the tail vein) with MDA-MB-231 human breast cancer cells (2×10⁷/animal), which was resuspended in 0.1 mL serum- and antibiotic-free culture medium containing 50% Matrigel (BD) and 50% DMEM (Hyclone). After inoculation, the animals were randomly divided into four groups (n=6), and treated as indicated in Table 1. For the low-dose and high-dose prevention group, 50 or 100 mg/kg baikalein was given by intragastric gavage for 15 days starting from the day after tumor cells were injected. Control group was given NS (normal saline). Four weeks after tumor cell injection, the therapy group began to receive 100 mg/kg baikalein by intragastric gavage everyday for up to 15 days. To examine the presence of metastases, the mice were sacrificed 8 weeks after the injection of tumor cells. Their lungs and livers were removed, fixed, sectioned, and stained with hematoxylin and eosin (H&E). Representative fields for each group were photographed and the number of metastases was counted.

Quantitative real-time RT-PCR
Total cell RNA was extracted using the MiniBEST Universal RNA Extraction Kit (TaKaRa, Tokyo, Japan) according to the manufacturer’s instructions. cDNA was synthesized with PrimeScriptTM RT Master Mix (TaKaRa). Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) reaction system was prepared following the instructions given in the SYBR®Premix Ex TaqII (Tli RNaseH Plus) RT-PCR Kit (TaKaRa) using 100 ng cDNA from each sample. Primers for specific genes investigated in this study are listed in Table 2. GAPDH was used as endogenous control. Each sample was analyzed in triplicate by using a StepOne™Real-Time PCR System (Thermo Fisher Scientific). Gene copy number data was analyzed in accordance with the 2-ΔΔCt method relative to expression of GAPDH and compared with the control.

Western blot analysis
MDA-MB-231 cells were separately treated with different concentrations of baikalein (0, 10, 20, and 40 μmol/L) for 24 and 48 hours. For comparing the protein level of SATB1, MCF-10A, MCF7, SKBR3, and MDA-MB-231 cells were directly lysed during their logarithmic growing phase. A total of 5×10⁶ cells of each group were suspended in 320 μL of ice-cold lysis buffer, a mixture of 1% B, C, and D components in RIPA (A), and allowed to settle on ice for 1 hour. For the lysis of tissue protein, modified RIPA buffer (containing 50 mM Tris pH 8.0, 150 mM NaCl, 0.02% NaN₃, 0.1% sodium dodecyl sulfate (SDS), 1% NP-40, 0.5% sodium deoxycholate, 1.56 mM protease inhibitor cocktail, 1 mM phenylmethanesulfonyl fluoride (PMSE), and 1 mM sodium orthovanadate) was used. Protein solutions from cell or tissue lysates were collected, and 15–20 μL of each sample (the quantity of total protein was made equal between all the groups) was separated by SDS–PAGE and transferred onto the polyvinylidene fluoride (PVDF) membranes (Millipore). The membranes were subsequently blocked in skim milk (5% in Tris-buffered saline with TWEEN 20 TBST buffer) at 25°C for 2 hours and then incubated at 4°C overnight with antibodies against SATB1, vimentin, SNAIL, E-cadherin, β-catenin, Wnt1, or β-actin in TBST containing 5% defatted milk separately. The membranes were then incubated with proper HRP-linked secondary antibody for 2 hours at 25°C. Finally, the bands were detected with an enhanced chemiluminescence kit (Thermo Fisher Scientific) and exposed by autoradiography using the chemiluminescence gel imaging system (G: BOX, Syngene, Cambridge, UK). The densitometric analysis was performed using Image-Pro Plus 6.0 (Media Cybernetics).

Table 1 Experimental grouping and treatment

<table>
<thead>
<tr>
<th>Group</th>
<th>Treatment</th>
<th>Number of mice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>IG + with NS</td>
<td>6</td>
</tr>
<tr>
<td>Therapy</td>
<td>IG 100 mg/kg baikalein</td>
<td>6</td>
</tr>
<tr>
<td>Low-dose²</td>
<td>IG 50 mg/kg baikalein</td>
<td>6</td>
</tr>
<tr>
<td>High-dose³</td>
<td>IG 100 mg/kg baikalein</td>
<td>6</td>
</tr>
</tbody>
</table>

Notes: ¹Intragastric gavage; ²Low-dose prevention group; ³high-dose prevention group.
Abbreviations: IG, intragastric gavage; NS, normal saline.
Immunohistochemistry

Effects of baicalein on the expression of target proteins in vivo were analyzed by immunohistochemistry. Metastatic lesions in the lung and liver of experimental mice were collected and paraffin-embedded. Then the paraffin-embedded tumor tissues were sliced into 5 μm sections. Antigen retrieval was performed with citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) in a domestic stainless steel pressure cooker at 120°C for 15 minutes. The sections were incubated with SATB1 (1:100), Wnt1 (1:50), β-catenin (1:50), E-cadherin (1:100), vimentin (1:100), and SNAIL (1:80) primary antibody at 4°C overnight, washed twice with PBS, and incubated with HRP-conjugated secondary antibody at room temperature for 30 minutes. Then the slides were washed and incubated with an Avidin–Biotin solution (Biocare Medical, Concord, CA, USA). Finally, sections were incubated with DAB and counterstained with H&E. Sections that were not incubated with primary antibody served as negative control. Images of sections were taken using Zeiss microscope (Zeiss Microscopy, Jena, Germany) and analyzed by Image-Pro Plus 6.0 (Media Cybernetics).

Statistical methods

Experiments were all repeated three times. SPSS 20.0 (IBM Corporation, Armonk, NY, USA) statistics software was applied to assess the statistical significance of differences in numerical data using the Student’s t-test. All statistical tests and corresponding P-values were two sided. P<0.05 was considered to be statistically significant.

Results

Baicalein inhibits the proliferation of MDA-MB-231 cells

The antiproliferation effects of baicalein (0–120 μmol/L) on MDA-MB-231 cells at different time points are shown in Table 3 and Figure 2. The proliferation potential of MDA-MB-231 cells was suppressed by baicalein in a dose- and time-dependent manner. IC_{50} of baicalein at 24, 48, and 72 hours were 89.71, 59.50, and 33.61 μmol/L, respectively. To exclude the obvious antiproliferative effect of baicalein, concentration range lower than 50 μmol/L was chosen for all subsequent experiments.

Baicalein suppresses the motility of MDA-MB-231 cells in vitro

Cancer cell motility predicts its metastasis potential, so wound healing assay was applied to evaluate the effect of baicalein on migration of MDA-MB-231 cells. As shown in Table 2, primers used for qRT-PCR analysis were as follows:

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primer sequence Forward (5′-3′)</th>
<th>Primer sequence Reverse (5′-3′)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SATB1</td>
<td>TGCAAGTTGCGAACCAGCAAAAGC</td>
<td>AAAATGCGTAATGTTGGGCGGTCCT</td>
</tr>
<tr>
<td>Axin2</td>
<td>CTGGCTCAGAAGACACAAAAG</td>
<td>ATCTCCTCAACACCGCTCA</td>
</tr>
<tr>
<td>Cyclin D1</td>
<td>ACCATCTTTCTCCAAGG</td>
<td>CACCAAGTGGCCACACAC</td>
</tr>
<tr>
<td>E-cadherin</td>
<td>TGGCCAGAAAAAGAAGG</td>
<td>GGTATAGGGCAATCGGTTCC</td>
</tr>
<tr>
<td>Vimentin</td>
<td>GAGAATTGTGCCGTTGAAGG</td>
<td>GCCTTCTGATTGGCAGAAT</td>
</tr>
<tr>
<td>SNAIL</td>
<td>TAGGCTGCTGAAAAGTGAAGT</td>
<td>GGGCTGCTGAAGTGAACC</td>
</tr>
<tr>
<td>GAPDH</td>
<td>TGGTCCCATATGGAACCTT</td>
<td>CTCACAGGCTACTAGCGG</td>
</tr>
</tbody>
</table>

Note: *P<0.05 and **P<0.01 compared with the control group.
Abbreviation: qRT-PCR, quantitative reverse transcription polymerase chain reaction.

<table>
<thead>
<tr>
<th>Concentration (μmol/L)</th>
<th>24 hours OD</th>
<th>24 hours IR (%)</th>
<th>48 hours OD</th>
<th>48 hours IR (%)</th>
<th>72 hours OD</th>
<th>72 hours IR (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.395±0.030</td>
<td>0</td>
<td>0.647±0.022</td>
<td>0</td>
<td>1.265±0.015</td>
<td>0</td>
</tr>
<tr>
<td>20</td>
<td>0.419±0.031</td>
<td>−6.08*</td>
<td>0.585±0.043</td>
<td>9.58*</td>
<td>1.118±0.006</td>
<td>11.59**</td>
</tr>
<tr>
<td>40</td>
<td>0.333±0.034</td>
<td>7.71**</td>
<td>0.475±0.033</td>
<td>26.58**</td>
<td>0.390±0.033</td>
<td>69.16**</td>
</tr>
<tr>
<td>60</td>
<td>0.308±0.021</td>
<td>11.50**</td>
<td>0.347±0.040</td>
<td>46.30**</td>
<td>0.179±0.021</td>
<td>85.87**</td>
</tr>
<tr>
<td>80</td>
<td>0.136±0.007</td>
<td>41.36**</td>
<td>0.214±0.033</td>
<td>66.92**</td>
<td>0.027±0.007</td>
<td>97.87**</td>
</tr>
<tr>
<td>100</td>
<td>0.107±0.013</td>
<td>47.95**</td>
<td>0.199±0.018</td>
<td>75.19**</td>
<td>0.023±0.014</td>
<td>98.17**</td>
</tr>
<tr>
<td>120</td>
<td>0.049±0.019</td>
<td>87.36**</td>
<td>0.068±0.026</td>
<td>89.49**</td>
<td>0.014±0.001</td>
<td>98.88**</td>
</tr>
</tbody>
</table>

Note: *P<0.05 and **P<0.01 compared with the control group.
Abbreviations: OD, optical density; IR, inhibition ratio.
Ma et al

Figure 3A, cells of the control group migrated into the wound area continuously and significantly as time progressed, compared to the baicalein-treated groups. After treatment with 10, 20, and 40 μmol/L baicalein for 24 hours, breast cancer cell motility was inhibited by 31.17%, 61.09%, and 74.15%, respectively (Figure 3B).

Baicalein inhibits the invasion of MDA-MB-231 cells in vitro

Invasion is another important aspect that shows the metastatic capacity of cancer cells. Thus, the classic method – Transwell in vitro invasion assay – was used to assess the invasion ability of MDA-MB-231 cells. Figure 4A shows that baicalein reduced the invasiveness of MDA-MB-231 cells in a concentration-dependent pattern. Quantification analysis

Figure 3

Baicalein inhibits the motility of MDA-MB-231 cells.

Notes: (A) Monolayers of MDA-MB-231 cells were wounded and then incubated in media containing 2% FBS with varying concentrations of baicalein (0, 10, 20, and 40 μmol/L) for 24 hours. Pictures were taken at 0, 12, and 24 hours after addition of baicalein. (B) Quantification of the wound healing assay. *P<0.05 compared with control; **P<0.01 compared with control. Data are presented as the mean ± SD of three separate experiments.

Abbreviations: FBS, fetal bovine serum; SD, standard deviation; h, hours.
indicated that after 24 hours, the invasive potential of MDA-MB-231 cells were suppressed by 32.04%, 54.59%, and 81.76% when cells were treated with 10, 20, and 40 μmol/L baicalein, respectively (Figure 4B).

**Baicalein suppresses breast cancer metastasis in vivo**

We evaluated the in vivo antitumor effects of baicalein by using the xenograft nude mouse model of breast cancer metastasis. After preventive or therapeutic treatment of baicalein, lung and liver tissues from each group were collected and analyzed. In the control group, obvious metastatic lesions in the liver (Figure 5A) and lung (Figure 6A) were visible to the naked eye. In all mice (6/6), liver and lung metastases were also detected when viewed under microscope (Figures 5C and 6C). In contrast, macroscopic nodules of the therapy or prevention group were rather smaller in size (Figures 5B and 6B), and some were hardly visible to the naked eye. At the microscopic level, baicalein treatment effectively reduced metastasis rate (liver: 4/6 in

---

**Figure 4** Baicalein inhibits the invasiveness of MDA-MB-231 cells.

**Notes:** (A) MDA-MB-231 cells were pretreated with 0, 10, 20, and 40 μmol/L baicalein for 24 hours and were then seeded in the upper wells. FBS (10%) was added to the bottom chambers for 24 hours to induce cell invasion. After 24 hours, cells on the bottom side of the filter were fixed, stained, and counted. (B) The percent invasion rate was expressed as a percentage of the control (0 μmol/L). Values represent the mean ± SD of three independent experiments performed in triplicate. **P < 0.01 compared with control group.

**Abbreviations:** FBS, fetal bovine serum; SD, standard deviation.
Figure 5: Baicalein suppresses liver metastasis of breast cancer in vivo.
Notes: Macroscopic findings of liver metastasis in the control group (A) and the high-dose prevention group (B). Microscopic findings of liver metastases in control group (C) and hardly seen metastatic lesions in high-dose prevention group (D). The black arrows show the lung metastases in each group, magnification of 100×.

Figure 6: Baicalein suppresses lung metastasis of breast cancer in vivo.
Notes: Macroscopic findings of lung metastasis in the control group (A) and the high-dose prevention group (B). (C) Histologically proven lung metastases in control group (100×). (D) Metastatic lesions are hardly to be seen in some mouse lung tissue of high-dose prevention group (100×). The black arrows show the lung metastases in each group.
therapy group, 5/6 in low-dose prevention group, and 3/6 in high-dose prevention group; lung: 3/6 in therapy group, 4/6 in low-dose prevention group, and 3/6 in high-dose prevention group) and, most importantly, the lesion size (Figures 5D and 6D).

**SATB1 expression correlates with the invasiveness of breast cancer cell lines**

To investigate the correlation between SATB1 and the invasiveness of breast cancer, we used Western blot to examine the protein level of SATB1 in four breast epithelial cell lines, including the immortalized mammary epithelial cells (MCF-10A), two nonmetastatic cancer cell lines (MCF7 and SKBR3), and one highly metastatic cancer cell line (MDA-MB-231). As shown in Figure 7A, SATB1 protein expression level is highest in MDA-MB-231 cell line, (significantly higher than in MCF7 and SKBR3 cell lines), while MCF-10A cells barely expressed SATB1 protein. Quantification analysis (Figure 7B) showed that when using MCF-10A as the internal reference, SATB1 protein expression level are 1.31-, 1.87-, and 4.21-fold in MCF7, SKBR3, and MDA-MB-231 cells, respectively, indicating that SATB1 expression is correlated with the invasive phenotype of breast cancer cells.

**Baicalein suppresses the expression of SATB1 in MDA-MB-231 cells**

A number of studies\(^9-18\) have indicated that SATB1 regulates the malignant progression of various cancers, including breast cancer, and its overexpression predicts poor outcome for cancer patients. To explore the possible antimetastatic mechanism of baicalein, the expression of SATB1 messenger RNA (mRNA) and protein were both examined in MDA-MB-231 cells treated with different concentrations of baicalein for 24 or 48 hours. As shown in Figure 8A, after treatment for 48 hours, 10, 20, and 40 \(\mu\)mol/L baicalein inhibited SATB1 mRNA expression by 21.58%, 37.29%, and 58.77%, respectively. Furthermore, SATB1 protein expression was suppressed by baicalein in a dose- and time-dependent manner compared with the control group (Figure 8B). Figure 8C showed that 10, 20, and 40 \(\mu\)mol/L baicalein inhibited the expression of SATB1 protein by 30.12%, 38.35%, and 59.18%, respectively, after 48 hours treatment.

**Baicalein regulates the expression of EMT-related molecules in MDA-MB-231 cells**

EMT is one of the crucial mechanisms by which tumor cells detach from their primary site and invade into surrounding tissues as well as the vascular system. It promotes metastasis during the malignant progression of epithelium-originated cancers.\(^34,35\) To investigate whether baicalein inhibits breast cancer cell metastasis through regulating EMT, we chose four representative molecules and assessed their expression levels in MDA-MB-231 cells after baicalein treatment. Expression of E-cadherin represents the epithelial phenotype, while vimentin is the molecular marker of mesenchymal cells. Transcription factor \textit{SNAIL} is regarded to be an important

\[ \text{Figure 7} \text{ SATB1 expression correlates with the invasiveness of breast cancer cell lines. Notes: (A) Western blot analysis of SATB1 levels in immortalized mammary epithelial cells (MCF-10A), non-aggressive breast cancer cell lines (MCF7 and SKBR3) and aggressive breast cancer cell line MDA-MB-231. (B) Quantification of the protein levels of SATB1. Values represent the mean ± SD of three independent experiments performed in triplicate. }^9 \text{ P}<0.05 \text{ and }^9 \text{ P}<0.01 \text{ compared with the control group.} \]

**Abbreviation:** SD, standard deviation.
suppressor of several epithelial markers, mainly E-cadherin, thus inducing EMT. MDA-MB-231 cells were treated with 0, 10, 20, and 40 μmol/L baicalein for 24 or 48 hours and then subjected to qRT-PCR or Western blot. Figure 9A shows that the inhibition rate of vimentin transcription level was approximately 12.31%, 27.93%, and 35.18% after 48 hours of treatment with 10, 20, and 40 μmol/L baicalein, respectively; and 10, 20, and 40 μmol/L baicalein downregulated the transcription level of \( \text{SNAIL} \) by 4.78%, 11.85%, and 26.08%, respectively, after 48 hours (Figure 10A). Figures 9B and 10B show that baicalein suppressed the protein expression of both vimentin and \( \text{SNAIL} \) in a dose- and time-dependent manner. The inhibition rate of vimentin protein was 16.47%, 28.92%, and 40.33% after 48 hours of treatment with 10, 20, and 40 μmol/L baicalein, respectively (Figure 9C). Figure 10C shows that 10, 20, and 40 μmol/L baicalein downregulated the protein level of \( \text{SNAIL} \) by 36.95%, 45.79%, and 58.83%, respectively, after 48 hours of treatment.

Figure 11A and B shows that baicalein upregulated the mRNA and protein levels of E-cadherin both in a dose- and time-dependent way. After treatment with 10, 20, and 40 μmol/L baicalein for 48 hours, the expression level of E-cadherin mRNA was increased to 1.49-, 2.45-, and 4.42-fold compared to the control. Further, Figure 11C shows that the expression level of E-cadherin protein was increased to 2.09-, 2.29-, and 2.56-fold, respectively.
Baicalein suppresses EMT and metastasis of breast cancer

It has been verified that deregulation of Wnt/β-catenin pathway may contribute to the progression of various cancers. To further investigate the possible mechanisms by which baicalein exerts its anticancer effect, Western blot was applied to assess the expression level of Wnt1 protein – one of the main ligands in the Wnt/β-catenin pathway. Figure 12A shows that baicalein suppressed the protein expression of Wnt1 in a dose- and time-dependent manner. The inhibition rate of Wnt1 protein was 46.68%, 58.13%, and 72.02% after 48 hours of treatment with 10, 20, and 40 μmol/L baicalein, respectively (Figure 12B).

β-Catenin is the key effector molecule in the Wnt/β-catenin pathway. A study found that the translocation of β-catenin from the cytoplasm to the nucleus plays an important role in promoting the expression of related genes of EMT. Figure 13A shows that the inhibition rate of β-catenin transcription level was approximately 5.93%, 66.55%, and 86.74% after 48 hours of treatment with 10, 20, and 40 μmol/L baicalein, respectively. Figure 13B shows that baicalein suppressed the protein expression of β-catenin
in a dose- and time-dependent manner. The inhibition rate of β-catenin protein was 11.09%, 23.30%, and 50.38% after 48 hours of treatment with 10, 20, and 40 μmol/L baicalein, respectively (Figure 13C).

Axin2 and Cyclin D1 are the downstream targets of the Wnt/β-catenin pathway. We used qRT-PCR to examine the effect of baicalein on the transcription level of Axin2 and Cyclin D1. Figure 14A shows that after treatment with 10, 20, and 40 μmol/L baicalein for 48 hours, the expression level of Axin2 mRNA was suppressed by 25.05%, 46.13%, and 61.24%, respectively. The inhibition rate of Cyclin D1 mRNA was also 4.62%, 11.38%, and 22.85% after 48 hours of treatment with 10, 20, and 40 μmol/L baicalein, respectively (Figure 14B).

**Baicalein downregulates the expression of SATB1, EMT, and Wnt/β-catenin pathway in vivo**

To further investigate the mechanisms involved in the antimetastatic effects of baicalein on breast cancer in vivo and acquire more reliable evidences to support our in vitro experimental findings, we applied immunohistochemistry as well as Western blot to evaluate the influence baicalein exerts on expression of various proteins studied in the
Figure 11 Baicalein increases the expression of E-cadherin in MDA-MB-231 cells. 
Notes: (A) The effects of baicalein on the expression levels of E-cadherin mRNA was assessed by qRT-PCR. (B) MDA-MB-231 cells were treated with baicalein (0, 10, 20, and 40 μmol/L) for 24 or 48 hours and then subjected to Western blotting to analyze the protein levels of E-cadherin. (C) Quantification of the protein levels of E-cadherin. Values represent the mean ± SD of three independent experiments performed in triplicate. **P<0.01 compared with the control group. 
Abbreviations: mRNA, messenger RNA; qRT-PCR, quantitative reverse transcription polymerase chain reaction; SD, standard deviation.

Figure 12 Baicalein inhibits the expression of Wnt1 in MDA-MB-231 cells. 
Notes: (A) MDA-MB-231 cells were treated with baicalein (0, 10, 20, and 40 μmol/L) for 24 or 48 hours and then subjected to Western blotting to analyze the protein levels of Wnt1. (B) Quantification of the protein levels of Wnt1. Values represent the mean ± SD of three independent experiments performed in triplicate. **P<0.01 compared with the control group. 
Abbreviation: SD, standard deviation.
Figure 13 Baicalein inhibits the expression of β-catenin in MDA-MB-231 cells.

Notes: (A) The effects of baicalein on the expression levels of β-catenin mRNA was assessed by qRT-PCR. (B) MDA-MB-231 cells were treated with baicalein (0, 10, 20, and 40 μmol/L) for 24 or 48 hours and then subjected to Western blotting to analyze the protein levels of β-catenin. (C) Quantification of the protein levels of β-catenin. Values represent the mean ± SD of three independent experiments performed in triplicate. *P < 0.05 and **P < 0.01 compared with the control group.

Abbreviations: mRNA, messenger RNA; qRT-PCR, quantitative reverse transcription polymerase chain reaction; SD, standard deviation.

previous in vitro assays. According to product datasheets of the primary antibodies, location of SATB1 or SNAIL in cells was mainly limited to the nucleus, but cytoplasmic staining also appears in some tissue sections. For Wnt1, β-catenin, E-cadherin, and vimentin, cytoplasmic (and membranous) staining was considered positive.

As shown in Figures 15 and 16, treatment of baicalein significantly suppressed the protein expression of SATB1, Wnt1, and β-catenin in the metastases of the mouse model, further verifying our previous findings that baicalein effectively downregulates SATB1 and Wnt/β-catenin signaling. In addition, vimentin and SNAIL expression in the control groups was much higher than in the therapy group and the two prevention groups, while increased expression of E-cadherin was observed in the baicalein-treated groups. These results suggest that baicalein inhibits, and even possibly, reverses the EMT that occurs during liver or lung metastasis of breast cancer in vivo. Statistical analysis proved the significant difference between control and other three experimental groups that was caused by baicalein.
treatment. Comparison between low-dose and high-dose prevention groups was also performed. The results indicate that baicalein downregulates the expression of SATB1, EMT, and Wnt/β-catenin pathway in a dose-dependent manner. Moreover, high-dose prevention treatment (IG 100 mg/kg) of baicalein exerts greater effects on expression of studied proteins (SATB1, Wnt1, β-catenin, E-cadherin, vimentin, and SNAIL) than therapy treatment (which began later). Expression differences of most of the analyzed proteins between the high-dose prevention group and therapy group are statistically significant (data not shown). These results indicate that early treatment with baicalein is more effective for the inhibition of tumor metastasis.

In addition to immunohistochemistry, Western blot was also performed to determine whether the in vivo antimetastatic effect of baicalein is associated with regulation of SATB1, EMT components, and Wnt/β-catenin signaling. Figure 17 shows that baicalein remarkably reduced the expression of SATB1, Wnt1, β-catenin, vimentin, and SNAIL, while increasing the expression of E-cadherin at the protein level, all in a dose-dependent manner. Results acquired by Western blot are in accordance with those of the immunohistochemistry assay, further verifying that treatment with baicalein can effectively inhibit the expression of SATB1 and downregulate Wnt/β-catenin pathway, which may cooperatively contribute to the prevention of EMT process and, eventually, suppress tumor metastasis in vivo.

Discussion

In recent years, the antitumor effect of the flavonoid baicalein has been confirmed in various cancers, including breast cancer. However, its antimetastatic effect and the specific mechanism(s) remain an unsolved problem. Our study revealed that baicalein significantly suppressed the in vitro metastatic potential of MDA-MB-231 cells possibly by inhibition of EMT via downregulation of SATB1 and Wnt/β-catenin pathway.

Normal human cells acquire uncontrolled proliferation ability through genetic variation, and resistance to apoptosis is the main mechanism of tumorigenesis. Immortalization of cancer cells also forms the biological basis for tumor growth and metastasis. We chose the highly metastatic breast cancer cell line MDA-MB-231 to investigate the antitumor effect of baicalein. According to the results of the MTT assay, we again confirmed that baicalein significantly inhibited the proliferation of MDA-MB-231 cells in a dose- and time-dependent manner. Wound healing assay has been widely used to assess the motility and migration ability of cells on the two-dimensional substratum. Tumor cells adhere to the basic membrane and extracellular matrix (ECM), secreting numerous proteases, such as...
Figure 15 Representative saTB1, Wnt1, β-catenin, E-cadherin, vimentin, and SNAIL expression in lung metastases of nude mouse model by immunohistochemistry.

Notes: (A1–4) Representative saTB1 expression. (B1–4) Representative Wnt1 expression. (C1–4) Representative β-catenin expression. (D1–4) Representative E-cadherin expression. (E1–4) Representative vimentin expression. (F1–4) Representative SNAIL expression. 1) Control group; 2) therapy group; 3) low-dose prevention group; 4) high-dose prevention group (100×).
Figure 16: Representative SATB1, Wnt1, β-catenin, E-cadherin, vimentin, and SNAIL expression in liver metastases of nude mouse model assessed by immunohistochemistry.

Notes: (A2-1–4) Representative SATB1 expression. (B2-1–4) Representative Wnt1 expression. (C2-1–4) Representative β-catenin expression. (D2-1–4) Representative E-cadherin expression. (E2-1–4) Representative vimentin expression. (F2-1–4) Representative SNAIL expression. 1) Control group; 2) therapy group; 3) low-dose prevention group; 4) high-dose prevention group.
as matrix metalloproteinases (MMPs), to degrade the ECM and then migrate through the normal biological barriers; these constitute the crucial steps occurring during tumor metastasis. Transwell in vitro invasion assay has been effectively applied to evaluate the invasiveness of cancer cells. Our results suggested that baicalein significantly suppressed the migration and invasion capacity of MDA-MB-231 cells in vitro compared to the control, both in a dose- and time-dependent manner.

SATB1 is a nuclear protein required for T-cell development. It combines with the AT-rich sequence in the genome and constitutes a functional nuclear architecture that has a “cage-like” structure, which is also termed as “the SATB1 regulatory network”. As a genome organizer, SATB1 regulates the expression of thousands of genes through recruiting chromatin remodeling/modifying enzymes and transcription factors, thus determining the classification of cell types and functions. Han et al. first revealed that SATB1 plays an important role during the progression of breast cancer. They pointed out that SATB1 is expressed during oncogenesis and reprograms the transcription profiles of breast tumors to promote tumor growth and metastasis. Silencing SATB1 in the highly metastatic breast cancer cell line MDA-MB-231 restored cell polarity; the invasive phenotype is reversed and cell metastatic capacity is significantly inhibited. Ectopic expression of SATB1 in the nonmetastatic breast cancer cell line SKBR3 led to gene expression patterns

![Image of Figure 17](https://example.com/image.png)

**Figure 17 (Continued)**
Baicalein suppresses EMT and metastasis of breast cancer

consistent with aggressive tumor-phenotype-induced cell invasiveness and enhanced cell metastatic activity in vivo. Although subsequent studies concerning various cancers have provided compelling evidences for the important function of SATB1 in cancer progression, there are dissenting views from some other research groups questioning this theory. Iorns et al\textsuperscript{45} found that the invasive ability of MDA-MB-231 cells was not suppressed after knocking down of SATB1. Upregulation of SATB1 in noninvasive cells did not promote cell invasiveness either. Furthermore, clinical statistical analysis showed no correlation between SATB1 and the overall survival of primary breast cancer patients. Similar opposition also came from a study concerning glioma.\textsuperscript{46}

To investigate whether SATB1 is associated with metastatic potential of breast cancer, we performed Western blot to examine the expression level of SATB1 protein in immortalized mammary epithelial cells MCF-10A, nonmetastatic breast cancer cell lines MCF7 and SKBR3, and highly
metastatic breast cancer cell line MDA-MB-231. Our results showed that the expression of SATB1 protein is positively related to the invasiveness of breast cancer cells, which is basically in accordance with the result of Han et al.9 To further study the antimetastatic mechanism of baicalein, we explored whether baicalein inhibits cell invasion by regulating the expression of SATB1. The results showed that baicalein significantly suppressed the expression of SATB1 mRNA and protein, both in a dose- and time-dependent pattern.

EMT happens when epithelial cells transform into mesenchymal phenotype during various physiological as well as pathological processes, such as embryonic development, fibrosis and wound healing, and tumor progression. Cells that have undergone EMT gain a higher invasive potential and acquire apoptosis resistance.57 EMT also induces the stemness of cells and participates in the regulation of immunosuppression.48 The biological activities that initiate and promote EMT process include activation of transcriptional factors, expression of certain cell-surface proteins, recognition and expression of cytoskeletal proteins, and production of ECM-degrading proteases.37

The β-catenin protein is a component of adherent junctions; it promotes cell adhesion by binding to the intracellular domain of the transmembrane protein cadherin.49 During EMT, β-catenin mediates the binding of cadherins and cytoskeleton, constitutes the transcription factor coactivation complex (β-catenin/TCF/LEF complex) with T-cell factor (TCF/LEF), which directly regulates EMT-associated genes, especially SNAIL.50,51 Transcriptional factor SNAIL has been proved to be the common downstream target shared by many signaling pathways that regulate EMT. SNAIL induces EMT through suppression of many epithelial markers, including E-cadherin and claudins (a family of proteins that are the most important components of tight junction). E-cadherin is one of the molecular markers of the epithelial phenotype; its expression decreases during EMT in embryonic development, fibrosis, and tumor progression.34,35 Downregulation or loss of E-cadherin results in the destruction of intercellular connection and contributes to metastasis of tumor cells, which is the most remarkable event during EMT.52 Vimentin remains a controversial marker of EMT. Many studies37,48,53 suggested that expression of vimentin positively correlates with the tumor metastasis; hence, it is regarded as a marker for cancer-related EMT.53 β-catenin also acts as the key effector molecule of the Wnt/β-catenin signaling pathway. In normal epithelial cells and nontumor cells, β-catenin is located on cell membrane; once EMT occurs, it translocates to the cytoplasm (dissociates from E-cadherin) or the nucleus (acts as transcription activator) and promotes the expression of related genes of EMT.56

Some studies suggested that the mechanism by which SATB1 regulates tumor metastasis is associated with its role in regulation of EMT. In breast cancer, Han et al9 found that SATB1 depletion blocks the upregulation of cell-structure genes typically seen in invasive breast cancers, among them vimentin and fibronectin. On the contrary, SATB1 depletion results in the upregulation of E-cadherin and β-catenin, and the E-cadherin suppressors – SNAIL and SIP1 – are also downregulated. Thus, EMT is reversed and breast cancer cells restore polarized cellular structures found in normal mammary epithelial cells. Similar results are mentioned in other studies regarding colon cancer54 and liver cancer.13

In this study, we examined the mRNA and protein level of E-cadherin, SNAIL, and vimentin in MDA-MB-231 cells that are pretreated with 0, 10, 20, and 40 μmol/L baicalein for 24 or 48 hours. Our results displayed that baicalein significantly downregulated SNAIL and vimentin while upregulating E-cadherin, all in a dose- and time-dependent manner. On the basis of the results obtained, two inferences can be drawn: 1) SATB1 contributes to breast cancer metastasis partly by regulating the EMT-associated molecules and promoting EMT and 2) the antimetastatic effect of baicalein is possibly associated with the downregulation of SATB1, and inhibition of EMT is probably the downstream effect.

The highly conserved canonical Wnt/β-catenin pathway is the most studied Wnt signal pathway. It plays a vital role in embryonic development and tissue homeostasis of adults.55 Deregulation of Wnt/β-catenin signaling is closely related to many diseases, including cancer.56 It has been suggested that Wnt/β-catenin is among the main pathways that regulate EMT, especially in tumor stem cells, which may be the key mechanism by which Wnt/β-catenin signal mediates breast cancer progression.36,57,58 Wnt1 is one of the canonical ligands for the Wnt/β-catenin pathway. Translocation into the nucleus as well as accumulation in cytoplasm of β-catenin indicates activation of Wnt/β-catenin pathway. Cyclin D1 and Axin2 are two downstream targets of Wnt/β-catenin pathway. Our study found that baicalein significantly inhibited the expression of Wnt1 and β-catenin in MDA-MB-231 cells and also suppressed the transcription level of both Cyclin D1 and Axin2, all in a dose- and time-dependent manner. These results indicate that baicalein inhibits breast cancer metastasis possibly by downregulating the activity of Wnt/β-catenin pathway.
In addition to the in vitro assays, the in vivo experiments have provided more evidence to support our findings in this study. We built the xenograft nude mouse model of breast cancer metastasis and performed a series of assays to explore the in vivo antimetastatic effects of baicalein. The results indicate that baicalein can effectively inhibit SATB1 protein expression, suppress EMT, and downregulate the Wnt/β-catenin pathway during lung and liver metastasis of breast cancer cells in vivo, which is in accordance with results from our in vitro assays.

It is known that SATB1 is mainly expressed in the T-cell lineage (thymocytes and TH2 cells) and plays multiple roles in the normal development of thymus and differentiation of pluripotent embryonic stem cells.5,6 Wnt/β-catenin signaling is also indispensable for the differentiation of T-cells and maturation of thymus.6,5 Notani et al7 found that SATB1 recruits β-catenin and regulates TH2 cells differentiation in a Wnt-dependent manner. In addition, Wnt/β-catenin and SATB1 share many target genes, such as c-Myc and Bcl-2.6,56,61 To sum up, the common involvement in regulation of thymus development, EMT, and stemness mentioned earlier indicate important associations between Wnt/β-catenin pathway and SATB1. We infer that they are also functionally connected during cancer progression. The question of whether the multifunctional “genome organizer” SATB1 exerts upstream regulation on Wnt/β-catenin pathway, and the mechanisms by which they interact with each other, warrants further studies.

Conclusion
In conclusion, we first report that baicalein has the potential to suppress MDA-MB-231 cells metastasis both in vitro and in vivo possibly by inhibition of EMT, which may be attributed to both downregulation of SATB1 and Wnt/β-catenin pathway. These findings provide a new perspective for the mechanisms involved in achieving the antimetastatic effect of baicalein and may serve as theoretical basics for therapeutic application of baicalein in antimetastatic therapy for breast cancer.

Ethics
Female Balb/c nude mice (4–8 weeks old, body weight 18–20 g) were purchased from Experimental Animal Center of Xi’an Jiaotong University (Xi’an, People’s Republic of China). Animal experiments performed in this study were conducted according to the recommended guidelines for the care and use of laboratory animals issued by the Chinese Council on Animal Research, and approved by the ethics committee of Xi’an Jiaotong University. Ethical approval for use of human cell lines was not needed as per Xi’an Jiaotong University ethical committee guidelines. The breast cancer cell lines used in this study are all commonly used and subcultured cell lines obtained from public cell banks. They were not derived from our patients or healthy donors.

Author contributions
SQZ directed and supervised this study and provided funding. XCM designed the experiments, conducted the entire cell in vitro assays, performed statistical analysis, and drafted the manuscript. WJY conducted the in vivo assays. XCM and WJY performed qRT-PCR, Western blot, and IHC. ZJD, XYG, and YNM provided technological advice on the project. QTX and JTJ consulted on the project and the manuscript. All authors have approved the content of the final manuscript.

Acknowledgments
This work was supported by the National Natural Science Foundation of China (Number 81274136, Number 81471670); Program for New Century Excellent Talents in Universities of China (Number NCET-110439); China Postdoctoral Science Foundation (Number 2014M560791, Number 2015T81037); and the Fundamental Research Funds for the Central Universities, People’s Republic of China (Number 2014qngz-04).

Disclosure
The authors report no conflicts of interest in this work.

References


